2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Molecular Testing, Omics Technologies, Bioinformatics, Computational Biology, Emerging Technologies, Profiling, Treatment Considerations, Combination Therapy, Therapy Sequence, Biological Therapies, Transplantation, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Artificial Intelligence (AI), Computer Vision, Machine Learning, Biological Processes, Pathogenesis, Genomics, Molecular Biology, Diseases, Lymphoid Malignancies, Plasma Cell Disorders, Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, Research, Translational Research, Clinical Research, Clinical Trials, Health Outcomes Research, Real-World Evidence, Study Population, Human, Adult, Elderly
PAPER

2311 Association between minimal residual disease negativity and progression-free survival in patients receiving belantamab mafodotin–based combinations for relapsed/refractory multiple myeloma: A pooled dreamm-7/dreamm-8 analysis

Suzanne Trudel, MD, Vania Hungria, MD, PhD2, Guldane Cengiz Seval, MD, PhD3, Sosana Delimpasi, MD4, Vladimir Vorobyev, MD, PhD5, Hang Quach, MBBS MD FRACP FRCPA6, Youngil Koh, MD7, Tadeusz Robak, MD8, Kihyun Kim, MD9, Sebastian Grosicki, MD PhD10, Hanlon Sia, MBBS, FRACP, FRCPA11, Marcelo Pitombeira de Lacerda, MD, PhD12, Andrey Garifullin, MD13, Felipe de Arriba14, Silvia Mangiacavalli, MD15, Benga Kazeem16, Jie Ma, PhD17, Ainslee Moore18, Kelly Brock, PharmD19, James Parker, PhD20, Joe Lee, MD, PhD21, Maria-Victoria Mateos Jr, MD, PhD22, Meletios-Athanasios (Thanos) C. Dimopoulos, MD23
1 Princess Margaret Cancer Centre, Toronto, Ontario, Canada
2 Clínica Médica São Germano, São Paulo, Brazil
3 Ankara University, Ankara, Turkey
4 General Hospital Evangelismos, Athens, Greece
5 Leningrad Regional Clinical Hospital, Saint Petersburg, Russian Federation
6 St. Vincent's Hospital Melbourne and University of Melbourne, Melbourne, VIC, Australia
7 Seoul National University Hospital, Seoul, Korea, Rep. of South
8 Medical University of Lódz, Lódz, Poland
9 Sungkyunkwan University, Samsung Medical Center, Seoul, Korea, Rep. of South
10 Medical University of Silesia, Katowice, Poland
11 Pindara Private Hospital, Gold Coast, QLD, Australia
12 Universidade da Região de Joinville and Centro de Hematologia e Oncologia, Joinville, Brazil
13 Russian Research Institute of Hematology and Transfusiology, Saint Petersburg, Russian Federation
14 Hospital General Universitario Morales Meseguer, IMIB-Pascual Parrilla, University of Murcia, Murcia, Spain
15 Fondazione I.R.C.C.S. Policlinico San Matteo, Pavia, Italy
16 GSK, Stevenage, United Kingdom
17 GSK, Waltham, MA, United States
18 GSK, Stevenage, United Kingdom
19 GSK, Collegeville, PA, United States
20 GSK, London, United Kingdom
21 GSK, London, United Kingdom
22 University Hospital of Salamanca/IBSAL/Cancer Research Center-IBMCC (USAL-CSIC), Salamanca, Spain
23 Korea University, Seoul, Korea, Rep. of South, National And Kapodistrian University Of Athens, Athens, Greece

Background

Targeting B-cell maturation antigen (BCMA) has demonstrated transformational survival benefits in patients (pts) with relapsed/refractory multiple myeloma (RRMM). Belantamab mafodotin (belamaf), a BCMA-targeting antibody-drug conjugate, in combination as triplet therapy, has demonstrated significant and clinically meaningful improvements in progression-free survival (PFS) (DREAMM-7 [D7] and DREAMM-8 [D8]) vs standard-of-care triplets, as well as significant overall survival (OS) benefit (D7) vs a daratumumab-based triplet in pts with RRMM who received ≥1 prior line of therapy (LOT). Minimal residual disease (MRD) negativity has been shown to be associated with prolonged PFS and improved survival outcomes in RRMM. Here, we characterize the association between MRD negativity, combined with a very good partial response or better (≥ VGPR), and PFS in a pooled analysis in pts treated with belamaf, bortezomib, and dexamethasone (BVd) or belamaf, pomalidomide, and dexamethasone (BPd) across the D7 and D8 studies.

 

Methods

In the phase 3, open-label trials D7 (NCT04246047) and D8 (NCT04484623), adults with RRMM and ≥1 prior LOT were randomized 1:1 to BVd or daratumumab, bortezomib, and dexamethasone (D7) and BPd or pomalidomide, bortezomib, and dexamethasone (D8). All pts in D8 were lenalidomide-exposed. The primary endpoint in both trials was independent review committee–assessed PFS. Secondary endpoints included OS, response rates, and MRD-negativity rates. This post hoc analysis characterized how MRD negativity combined with response is associated with PFS in a pooled analysis in pts treated with BVd or BPd across the D7 and D8 trials. As MRD status and clinical response changed over time, time-varying proportional hazards models (univariate and multivariable) were used to assess the association of MRD with the response group and PFS. Targeted next-generation sequencing in a central testing laboratory was used to assess MRD status at a sensitivity threshold of 10−5. Baseline MRD status was considered positive in all pts before initiation of treatment. MRD testing occurred when a pt first achieved a confirmed response of ≥ VGPR and was repeated every 6 months until disease progression. Multivariable models also included baseline age, Revised International Staging System (R-ISS) stage, number of prior LOT, renal function, cytogenetic risk, and lenalidomide-refractory status as covariates. Hazard ratios (HRs) for PFS were estimated using a time-varying Cox model. Median PFS was estimated using the Kaplan-Meier method, with 95% CIs based on the Brookmeyer-Crowley method. All P values are nominal. Data cutoffs for this analysis were October 7, 2024, for D7 and July 7, 2025, for D8.

 

Results

Of the 398 BVd and BPd pts pooled from the D7 and D8 trials, 259 (65%) pts achieved ≥ VGPR, of whom 58% [149/259] achieved MRD negativity. At a median follow-up of 39.4 months for D7 and 35.8 months for D8, median PFS was not reached in pts who achieved ≥ VGPR and MRD negativity (NR; 95% CI, 47.7 months-NR). At the 24-month landmark, the estimated PFS rate was 84% in pts who achieved ≥ VGPR and MRD negativity. A time-varying Cox proportional hazards model demonstrated that ≥ VGPR and MRD negativity were associated with improved PFS in univariate (HR 0.23; 95% CI, 0.15-0.35; P<0.00001) and multivariable analyses (HR 0.22; 95% CI, 0.14-0.34; P<0.00001) compared with < VGPR or MRD positivity. Multivariable analyses also showed that improved PFS was associated with R-ISS stage I vs stage III and with normal baseline renal function (≥90 mL/min) vs moderate renal impairment (≥30 to <60 mL/min). Correspondingly, pts with R-ISS stage III had a higher risk of progression or death than those with stage I (HR 2.19; 95% CI, 1.31-3.67; P=0.0028), and pts with moderate renal impairment had a higher risk than those with normal renal function (HR 1.71; 95% CI, 1.10-2.65; P=0.0163). The positive association of ≥ VGPR and MRD negativity on PFS persisted even when accounting for differences in age, prior LOT, cytogenetic risk, and lenalidomide-refractory status.

 

Conclusions

In this pooled analysis of belamaf-containing triplets, achieving ≥ VGPR and MRD negativity was associated with extended PFS, supporting the value of evaluating both clinical response and MRD-assessed depth of response when considering potential PFS benefit in pts with RRMM treated with belamaf-based combinations. 

 

Suzanne Trudel, MD: AstraZeneca - Honoraria; Amgen - Honoraria; Forus - Honoraria; Pfizer - Honoraria; GlaxoSmithKline - Honoraria; Janssen - Honoraria; Sanofi - Honoraria; Bristol-Myers Squibb - Research Funding; Janssen - Research Funding; Pfizer - Research Funding; RapidNovor - Research Funding; GlaxoSmithKline - Research Funding; K36 Therapeutics - Research Funding; AstraZeneca - Research Funding; AstraZeneca - Consultancy (Includes expert testimony); Janssen - Consultancy (Includes expert testimony); Bristol-Myers Squibb - Consultancy (Includes expert testimony); Roche - Consultancy (Includes expert testimony); Sanofi - Consultancy (Includes expert testimony); Pfizer - Consultancy (Includes expert testimony); GlaxoSmithKline - Consultancy (Includes expert testimony)